[Skip to Navigation]
Comment & Response
May 2018

Depression Screening in Dermatology—Think Isotretinoin

Author Affiliations
  • 1Department of Dermatology, University Hospitals Cleveland Medical Center, Cleveland, Ohio
  • 2Northeast Ohio Medical University, Akron
  • 3Akron Dermatology, Akron, Ohio
JAMA Dermatol. 2018;154(5):629-630. doi:10.1001/jamadermatol.2018.0085

To the Editor We applaud McDonald et al for publishing “The PHQ-2 in Dermatology—Standardized Screening for Depression and Suicidal Ideation.”1 The importance of this work cannot be overemphasized. We agree that dermatologists are uniquely situated to identify psychiatric concerns related to skin disease, and the PHQ-2 (Patient Health Questionnaire-2)2 is a great screening tool for this. Since we published on the use of the PHQ-2 in the context of isotretinoin,3 we have had positive feedback on its use and wish to reemphasize the importance in association with the article by McDonald et al. Additionally, we believe that their algorithmic approach warrants an expansion.

Add or change institution